Decreased CD27 on B lymphocytes in patients with primary hepatocellular carcinoma

Journal of International Medical Research

Volumn 40, Issue 1, 2012, Pages 307-316

  Wang, X D ^a   Wang, L ^a   Ji, F J ^a   Zhu, J M ^a   Ayana, D A ^b   Fang, Xue Dong ^a  

^a JILIN UNIVERSITY   (China)

^b HARAMAYA UNIVERSITY   (Ethiopia)

Author keywords

B lymphocytes; CD27; Cytokines; Hepatitis B virus; Hepatocellular carcinoma; Interleukins

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA1 INTEGRIN; CD19 ANTIGEN; CD27 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; LIVER CELL CARCINOMA; MALE; MEMORY CELL; PERIPHERAL LYMPHOCYTE;

EID: 84863255584     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000131     Document Type: Article

References (29)

1. Mohandas KM: Hepatitis B associated hepatocellular carcinoma: epidemiology, diagnosis and treatment. Hep B Annual 2004; 1: 140-152.
2. Bréchot C: Pathogenesis of hepatitis B virusrelated hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 suppl 1): S56-S61.
3. Fatourou EM, Koskinas JS: Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications. Expert Rev Anticancer Ther 2009; 9: 1499-1510.
4. Kong L, Yao SK, Liu JX, et al: The prognostic value of cellular immunity function in patients with hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2005; 13: 194-197 [in Chinese, English abstract].
5. Löhr H, Goergen B, Weber W, et al: Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: cellular immune reactions and response to interferon treatment. J Med Virol 1994; 44: 330-335.
6. Jeong SH: HBV infection as a risk factor for non-Hodgkin lymphoma. Lancet Oncol 2010; 11: 806.
7. Tangye SG, Liu YJ, Aversa G, et al: Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998; 188: 1691-1703.
8. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998; 188: 1679-1689.
9. -(naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005; 17: 383-390.
10. -(naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2004; 20: 621-629.
11. Stamataki Z, Shannon-Lowe C, Shaw J, et al: Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 2009; 113: 585-593.
12. Inokuchi M, Ito T, Uchikoshi M, et al: Infection of B cells with hepatitis C virus for the development of lymphoproliferative disorders in patients with chronic hepatitis C. J Med Virol 2009; 81: 619-627.
13. Fan HB, Zhu YF, Chen AS, et al: B-cell clonality in the liver of hepatitis C virus-infected patients. World J Gastroenterol 2009; 15: 1636-1640.
14. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
15. Child CG: Surgery and portal hypertension. In: The Liver and Portal Hypertension (Child CG, ed). Philadelphia: WB Saunders, 1964; pp 50-72.
16. Pugh RN, Murray-Lyon IM, Dawson JL, et al: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.
17. Llovet JM, Fuster J, Bruix J, et al: The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(suppl 1): S115-S120.
18. Vitale A, Morales RR, Zanus G, et al: Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011; 12: 654-662.
19. Jiang Y, Li W, Yu L, et al: Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell Mol Immunol 2011; 8: 75-82.
20. Li WY, Jiang YF, Jin QL, et al: Immunologic characterization of posthepatitis cirrhosis caused by HBV and HCV infection. J Biomed Biotechnol 2010; 2010: 138237.
21. Ahmad SF, Pandey A, Kour K, et al: Downregulation of pro-inflammatory cytokines by lupeol measured using cytometric bead array immunoassay. Phytother Res 2010; 24: 9-13.
22. Ward SM, Phalora P, Bradshaw D, et al: Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus. J Infect Dis 2008; 198: 813-817.
23. Chi SW, Kim J, Yi GS, et al: Broadly neutralizing anti-HBV antibody binds to non-epitope regions of preS1. FEBS Lett 2009; 583: 3095-3100.
24. Watts NR, Cardone G, Vethanayagam JG, et al: Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids. J Mol Biol 2008; 379: 1119-1129.
25. Vallat L, Benhamou Y, Gutierrez M, et al: Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004; 50: 3668-3678.
26. Moritoki Y, Tsuda M, Tsuneyama K, et al: B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD. c3c4 model of autoimmune cholangitis. Cell Immunol 2011; 268: 16-23.
27. Lund FE: Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 2008; 20: 332-338.
28. Llorente L, Zou W, Levy Y, et al: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839-844.
29. Youinou P, Hillion S, Tobón GJ, et al: Pharmacological role and clinical applications of interleukin-6 in rheumatoid disease. Int J Interferon Cytokine Mediator Res 2010; 2: 33-39.